Phase 2 × Nivolumab × Thoracic × Clear all
NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio, Inc.

Phase 2 Active not recruiting
40 enrolled
NCT06265285 2025-12-04

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Mayo Clinic

Phase 2 Recruiting
50 enrolled
NCT06638931 2025-05-28

ANTARES

Instituto do Cancer do Estado de São Paulo

Phase 2 Active not recruiting
28 enrolled